I'll give my 2 cents.
I wouldn't expect much in way of revenue from sales from last quarter, possibly around the previous quarter of $1.1 million usd. If it is greater than this because of ViraDx and early FebriDx sales then it will be a bonus, as uptake is really only starting. Cash burn is currently assumed to be around $2.5 million usd per quarter while things are ramping up.
The revenue that will make the quarterly look amazing (assuming it is added), is the first payment from Hologic of around $5 million usd from the recent contract. Adding this will boost revenue over last quarter by around 500%, which would be a big headline in the upcoming announcement.
Realistically sales from things like FebriDx in particular is unlikely to gain real traction till CLIA waiver and sales to clinics which will hopefully start to reflect in the next quarter.
All IMHO. We will know for certain when the quarterly comes out.
Add to My Watchlist
What is My Watchlist?
